Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24906929 | 0.90 | NPSR1 (0.36) | NPSR1CHRM1 | |
| SCHEMBL17682229 | 0.84 | NPSR1 (0.35) | NPSR1 | |
| SCHEMBL1502417 | 0.83 | NPSR1 (0.36) | NPSR1CHRM1 | |
| SCHEMBL1502449 | 0.81 | KDM4E (0.41) | NPSR1CHRM1 | |
| SCHEMBL14358409 | 0.81 | NPSR1 (0.34) | NPSR1CHRM1 | |
| SCHEMBL23369954 | 0.80 | CHRM1 (0.38) | NPSR1CHRM1HSD11B1 | |
| SCHEMBL6921477 | 0.77 | NPSR1 (0.32) | NPSR1 | |
| SCHEMBL15589146 | 0.77 | CYP4F2 (0.42) | NPSR1 | |
| SCHEMBL22233967 | 0.76 | CYP3A4 (0.47) | CHRM1 | |
| SCHEMBL30091372 | 0.74 | ALDH1A1 (0.42) | NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348363-A1 | COMPOUNDS AND THEIR USE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2023-11-02 | — | — | US | disclosed |
| US-11667602-B2 | Compounds and their use | ASTRAZENECA AB (SE) | 2023-06-06 | — | — | US | disclosed |
| US-20230026801-A1 | SSAO INHIBITORS AND USE THEREOF | ECCOGENE INC. | 2023-01-26 | — | — | US | disclosed |
| WO-2022122773-A1 | 4-(2-FLUORO-4-METHOXY-5-3-(((1-METHYLCYCLOBUTYL)METHYL)CARBAMOYL)BICYCLO[2.2.1]HEPTAN-2-YL)CARBAMOYL)PHENOXY)-1-METHYLCYCLOHEXANE-1-CARBOXYLIC ACID DERIVATIVES AND SIMILAR COMPOUNDS AS RXFP1 MODULATORS FOR THE TREATMENT OF HEART FAILURE | ASTRAZENECA AB (SE) | 2022-06-16 | — | — | WO | disclosed |
| US-20210147360-A1 | SSAO INHIBITORS AND USE THEREOF | ECCOGENE INC. | 2021-05-20 | — | — | US | disclosed |
| WO-2021083209-A1 | SSAO INHIBITORS AND USE THEREOF | ECCOGENE (SHANGHAI) CO., LTD. (CN) | 2021-05-06 | — | — | WO | disclosed |
| US-7915252-B2 | Sulfonyl compounds as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1 | MERCK SHARP & DOHME (US) | 2011-03-29 | — | — | US | disclosed |
| US-20080318930-A1 | Sulfonyl Compound as Inhibitors of 11-Beta-Hydroxysteroid Dehydrogenase-1 | MERCK SHARP & DOHME LLC | 2008-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11667602-B2 | Compounds and their use | RXFP1, RXFP3, RXFP2 | NPSR1 255/4885CHRM1 50/4885HSD11B1 1542/4885 |
| US-20230348363-A1 | COMPOUNDS AND THEIR USE | RXFP1, RXFP3, RXFP2 | NPSR1 255/4885CHRM1 50/4885HSD11B1 1542/4885 |
| US-20230026801-A1 | SSAO INHIBITORS AND USE THEREOF | SSB, HAO1, SORD | NPSR1 1640/4885CHRM1 3049/4885HSD11B1 107/4885 |
| US-20080318930-A1 | Sulfonyl Compound as Inhibitors of 11-Beta-Hydroxysteroid Dehydrogenase-1 | HSD11B1, HSD17B1, HSD11B2 | NPSR1 2652/4885CHRM1 3378/4885HSD11B1 1/4885 |
| US-20210147360-A1 | SSAO INHIBITORS AND USE THEREOF | SSB, HAO1, SORD | NPSR1 1640/4885CHRM1 3049/4885HSD11B1 107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.